Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-12-17
DOI
10.3389/fonc.2019.01416
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model
- (2019) Paige Baldwin et al. Frontiers in Oncology
- Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform
- (2016) Y. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
- (2014) Edwin Choy et al. BMC CANCER
- Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
- (2014) M. A. Smith et al. CLINICAL CANCER RESEARCH
- Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
- (2014) Britta Vormoor et al. CURRENT OPINION IN ONCOLOGY
- Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program:PALB2mutation predicts exceptionalin vivoresponse to BMN 673
- (2014) Malcolm A. Smith et al. PEDIATRIC BLOOD & CANCER
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
- (2012) J. C. Brenner et al. CANCER RESEARCH
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- Ewing Sarcoma: Clinical State-of-the-Art
- (2012) Jenny Potratz et al. PEDIATRIC HEMATOLOGY AND ONCOLOGY
- Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
- (2011) J. Chad Brenner et al. CANCER CELL
- PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
- (2009) Jason Park et al. Nanomedicine-Nanotechnology Biology and Medicine
- Changes in Incidence and Survival of Ewing Sarcoma Patients Over the Past 3 Decades
- (2008) Natia Esiashvili et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks
- (2008) X. Liu et al. MOLECULAR CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started